FDA Clearance Tracker · P170024-S003
Surpass Evolve Flow Diverter System
Last checked: Nov 20, 2026Latest source record: May 20, 2020 (this decision)Source: openFDAMethods & limitations
Decided
May 20, 2020
Approved
Time to decision
443 days
Received Mar 4, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P170024-S003
- Device name
- Surpass Evolve Flow Diverter System
- Applicant
- Stryker Neurovascular
- Applicant location
- Fremont, CA
- Received
- Mar 4, 2019
- Decided
- May 20, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P170024
Device type
- Device type
- Intracranial aneurysm flow diverter (OUT)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for a change in the design of the approved Surpass Streamline Flow Diverter that consists of a new delivery system, smaller gauge wire in the stent to enable delivery through a smaller microcatheter, and reduce the number of cobalt chromium wires used in the stent braid.
Source documents
Other decisions for Stryker Neurovascular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261649 · Decided Oct 9, 2026 · 143 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.